title: Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
abstract: OBJECTIVE
  To compare the combination of paclitaxel (Taxol; Bristol-Myers Squibb, Princeton, NJ, http://www.bms.com) and topotecan (Hycamtin; Glaxo SmithKline, Philadelphia, http://www.gsk.com) with paclitaxel, carboplatin (Paraplatin; Bristol-Myers Squibb), and etoposide (Etopophos, VePesid; Bristol-Myers Squibb) in patients with previously untreated extensive-stage small cell lung cancer.
  
  
  METHODS
  In this phase II trial, 120 patients were randomly allocated to receive either topotecan (1.5 mg/m(2) i.v. days 1, 2, and 3) and paclitaxel (175 mg/m(2) i.v. day 1) every 21 days orpaclitaxe l (200 mg/m(2) i.v. day 1), carboplatin (area under the concentration-time curve 6 i.v. day 1), and etoposide (50 mg/100 mg alternating daily by mouth days 1-10) every 21 days, each regimen for a maximum of eight cycles. The primary end points were objective response rate and time to progression.
  
  
  RESULTS
  The paclitaxel-carboplatin-etoposide combination produced a significantly higher overall response rate (78% versus 48%), longer median time to progression (7.6 months versus 5.5 months), and greater number of patients free from progression at 1 year (14% versus 8%) compared with paclitaxel plus topotecan. There was no difference in overall survival. Toxicities were similar in the two treatment arms.
  
  
  CONCLUSIONS
  The paclitaxel-carboplatin-etoposide combination produced a superior overall response rate and time to progression in patients with extensive-stage small cell lung cancer compared with paclitaxel plus topotecan. The platinum compounds continue to be a necessary component of the initial therapy for these patients.
authors.affiliation: Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA. fgreco@tnonc.com
authors.forename: F Anthony
authors.initials: FA
authors.lastname: Greco
authors.forename: Dana S
authors.initials: DS
authors.lastname: Thompson
authors.forename: Lisa H
authors.initials: LH
authors.lastname: Morrissey
authors.forename: Joan B
authors.initials: JB
authors.lastname: Erland
authors.forename: Howard A
authors.initials: HA
authors.lastname: Burris
authors.forename: David R
authors.initials: DR
authors.lastname: Spigel
authors.forename: Geetha
authors.initials: G
authors.lastname: Joseph
authors.forename: Steven W
authors.initials: SW
authors.lastname: Corso
authors.forename: Ellen
authors.initials: E
authors.lastname: Spremulli
authors.forename: John D
authors.initials: JD
authors.lastname: Hainsworth
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000401:mortality; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000009:adverse effects; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D019772:Topotecan / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D009943:Organophosphorus Compounds; C061400:etoposide phosphate; D005047:Etoposide; D019772:Topotecan; D016190:Carboplatin; D017239:Paclitaxel